GEN Exclusives

More »

Jun. 1, Vol. 32, No. 11

      • Emerging Markets Turn to Innovation
      • G. Steven Burrill
      • In April 2011, Ascletis launched with $100 million in backing from a Chinese billionaire to discover and develop new treatments for cancer and infectious diseases in China. The company’s management team, based in Chapel Hill, NC, is made up of seaso ... more »
      • Finding the Right Balance in HPLC
      • Josh P. Roberts
      • Everything in chromatography is a compromise. It’s like a game, trying to come up with the best system of compromises that gives you the optimum platform for the separation process. “There are lots of ways you can do it,” explains Jack (J.J.) Kirk ... more »
      • Reprogramming Alters Cells’ Fate
      • Kathy Liszewski
      • The electrifying possibility of reprogramming human cells to different fates has huge ramifications for human therapeutics. The technology is gaining momentum as scientists make headway to better understand the molecular and cellular aspects of repr ... more »
      • U.K. Biopharma Bouncing Back
      • Sue Pearson, Ph.D.
      • 2012 is looking like a better year for the U.K.’s biopharm sector. Recently, a pharma heavyweight entered the ring and is banking on the region’s biomanufacturing abilities. GlaxoSmithKline recently announced an investment of over £500 millio ... more »
    • Corporate Profiles

      • Keeping Cell Cultures Contamination Free
      • Carol Potera
      • Bioprocessing operations face the threat that bacteriophages (viruses that infect bacteria) will infect the cell cultures used to manufacture biotherapeutic proteins in bioreactors. Contamination with bacteriophages, also known as phages, may comple ... more »
    • BioMarket Trends

      • Outsourcing Discovery Can Stretch Dollars
      • Bruce Carlson
      • Outsourcing has become so paramount to a pharmaceutical firm’s strategy that it is a given that noncore functions will be outsourced. Core functions, however, like the discovery of potential new drugs, used to remain in house. This pattern has been ... more »
    • Assay Tutorials

    • Gene Therapy Briefs

      • Gene Therapy Briefs
      • Amsterdam Molecular Therapeutics (AMT) lost its appeal to EMA’S Committee for Medicinal Products for Human Use (CHMP), which maintained a previous recommendation that the company’s gene therapy Glybera® (alipogene tiparvovec) should not be gr ... more »
    • People in the News

      • People in the News
      • EMD Millipore promoted Andrew Bulpin, Ph.D. , to head of global pharmaceutical chemicals solutions sales. Dr. Bulpin joined Millipore in 2006 as vp for the upstream processing business unit and assumed leadership of the services and solutions busine ... more »
    • Application Note

      • Advertorial: DSM Pharma Biotechnology
      • Our main focus at DSM is to create brighter lives for people today and for generations to come. DSM Pharmaceutical Products is a leading pro­vider of high-quality custom contract manufacturing, development services, and optimizing technologies ... more »

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?